Tripep AB expands the new issue of shares and raises another SEK 2 million

The Board of Directors of Tripep AB has, based on the authorization by the AGM, resolved to raise another SEK 2 million through the issue of 4,000,000 shares at SEK 0.50 per share. The new issue is made without preferential rights for existing shareholders and has been subscribed by existing shareholders. The proceeds will be used as working capital. The issue of 4,000,000 shares will increase the number of shares in the company to 33,575,314. For more information, please contact: Anders Vahlne, CEO & Head of Research, Tripep AB Tel: +46 8 5858 1313, Mobile phone: +46 709 28 05 28 E-mail: anders.vahlne@ki.se About Tripep Tripep develops drugs against chronic disease based on proprietary and other parties’ patented and patent pending technologies. Tripep is focusing on the following research projects; wound healing therapy ChronSeal® and a therapeutic vaccine against Hepatitis C, named ChronVac-C®, plus the RAS® technology platform. The Tripep share is admitted to trade on First North. Remium AB is Certified Adviser for Tripep AB. For more information, please refer to the company’s website:www.tripep.se. In the event of any discrepancy between the Swedish and English versions of this press release, the Swedish version will take precedence.